In a Dec. 5 letter, the agency wrote Valisure that its online pharmacy failed to take several basic steps to ensure that suspect or illegitimate medicines were investigated and that distributors were alerted. Moreover,the FDA cited its laboratory for “methodological deficiencies” in testing medicines over concerns that the results may dissuade its customers from purchasing certain medicines.
2 years after pushing FDA to analyze Nitrosamines, Valisure cited it for failing to comply with federal law
Regulatory Focus published an article for this alert. The Valisure tested only for informational purposes, not for any regulatory purpose.
Is this the same company whose methodology was criticized in the recent Zantac judgement MDL NO. 2924?
You are right…its same Valisure